Patients' views of interferon therapy in MS

Interferon beta-1b is a new and somewhat controversial drug therapy used in the management of MS. In this study people using interferon beta-1b reported fewer relapses, less use of their primary health-care services and an overall improvement in their condition. Outcome measures for use in MS need to be more sensitive in order to measure effectively the impact of therapies such as interferon beta-1b and beta-1a. Further research using validated quality-of-life scales to fully assess the impact of these new treatments is urgently needed.